Biblio
.
TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma. Nat Commun. 2022;13(1):5676.
FOXA2 Is Required for Enhancer Priming during Pancreatic Differentiation. Cell Rep. 2019;28(2):382-393.e7.
.